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Background: Human gliomas are a heterogeneous group of primary malignant brain tumors whose molecular
pathogenesis is not yet solved. In this regard, a major research effort has been directed at identifying novel
specific glioma-associated genes. Here, we investigated the effect of TRIM8 gene in glioma.
Methods: TRIM8 transcriptional level was profiled in our own glioma cases collection by qPCR and confirmed in the
independent TCGA glioma cohort. The association between TRIM8 expression and Overall Survival and Progression-
free Survival in TCGA cohort was determined by using uni-multivariable Cox regression analysis. The
effect of TRIM8 on patient glioma cell proliferation was evaluated by performing MTT and clonogenic assays. The
mechanisms causing the reduction of TRIM8 expression were explored by using qPCR and in vitro assays.
Results: We showed that TRIM8 expression correlates with unfavorable clinical outcome in glioma patients. We
found that a restored TRIM8 expression induced a significant reduction of clonogenic potential in U87MG and
patient’s glioblastoma cells. Finally we provide experimental evidences showing that miR-17 directly targets the
3′ UTR of TRIM8 and post-transcriptionally represses the expression of TRIM8.
Conclusions: Our study provides evidences that TRIM8 may participate in the carcinogenesis and progression of
glioma and that the transcriptional repression of TRIM8 might have potential value for predicting poor prognosis in
glioma patients.
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Human gliomas are a heterogeneous group of primary
malignant brain tumors, which most commonly occur in
central nervous system of both children and adults [1].
Glioblastoma multiforme (GBM), the most aggressive
form of glioma, exhibits advanced features of malignancy,
such as rapid tumor cell proliferation, intense apoptosis
resistance, florid necrosis, and robust angiogenesis [2].
The tumor properties underlie the poor clinical outcome
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creativecommons.org/publicdomain/zero/1.0/radiotherapy, and by promoting a neurologically debilitat-
ing course leading to death within 12–18 months post
diagnosis [3]. TRIM8 maps to chromosome 10q24.3, a re-
gion showing frequent deletion and loss of heterozygosity
in human glioma [4]. TRIM8 encodes a member of the
tripartite-motif-containing (TRIM) protein super family
involved in a broad range of biological processes, includ-
ing carcinogenesis [5]. TRIM8 interacts with and
negatively regulates PIAS3, a protein inhibitor of IL-6-
dependent activation of STAT3, a signaling pathway
important for cancer development and progression [6]. In
agreement with previously data, we recently reported
TRIM8 as a new modulator of the p53-mediated tumor
suppression mechanism [7]. Under stress conditions, suchticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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sion of TRIM8, which in turn stabilizes p53 leading to cell
cycle arrest and reduction of cell proliferation through en-
hancement of p21 and GADD45 expression [7]. Experi-
mental evidence has outlined TRIM8 as one of the genes
which low expression level correlates with nodal meta-
static progression in primary larynx squamous cell carcin-
oma and whose expression inhibits tumor cell colony
formation in vitro [8]. Finally, TRIM8 deficit has been
showed to impair p53-mediated cellular responses to che-
motherapeutic drugs in a model of Renal Cell Carcinoma
[9]. Up regulation of miR-17, associated with advanced
tumor progression and poor overall survival of gliomas
[10], has been shown to reduce the levels of TRIM8 in
primary chronic lymphocytic leukemia cells, although a
direct regulation was not yet demonstrated [11].
In this study, we showed that TRIM8 is down regu-
lated in glioma tissues and cell lines and its expression
inversely correlates with tumor grade. We found that a
restored TRIM8 expression in patient glioma cell lines
suppresses the tumor growth and induced a significant
reduction of clonogenic potential. Finally we showed
that miR-17 directly targets the 3′UTR of TRIM8 and
post-transcriptionally represses the expression of TRIM8.
Methods
Patients and samples
In this study we collected 70 specimens at the time of sur-
gery from the Neurosurgery Unit IRCCS, Casa Sollievo
della Sofferenza (CSS), San Giovanni Rotondo, Italy. The
Ethic Committees of the IRCCS, CSS, approved this study.
Prior written and informed consent was obtained from
each patient in accordance with Institution Guidelines
and acceptance. Upon receipt from surgery, one half of
the tissue sample from the bulk of the tumor was immedi-
ately frozen in liquid nitrogen and stored at −80 °C. The
second half was processed for primary tumor cultures.
After surgery, glioblastoma patients were treated accord-
ing to the Stupp protocol [12]. All cases were newly diag-
nosed gliomas, pathologically classified according to the
WHO system. Clinical-pathological patients’ characteris-
tics are reported in Additional file 1: Table S1. The median
follow up time along with interquartile range (IQR) was
17.8 (IQR: 10.7-27.7) months.
Primary tumor cell cultures generation
Glioma samples were mechanically disassociated into
single cells using sterile scalpels. Tumor short-term cells
suspension was cultured in a poly-lysine-coated T25
flask at 37 °C and 5 % CO2 and expanded in DMEM/
F12 medium containing 10 % foetal calf serum, 1 %
penicillin/streptomycin. Human U87MG glioma cell
lines were grown following standard protocols. All cell
culture media were purchased from Life Technologies.We were successful in obtaining primary cell culture for
45 glioma patients. Additional RNAs and DNAs from
glioma-derived cell lines were reported in [13] and pro-
vided by Dr. Daga, IST, Genova. Normal human astrocyte
(NHA) cell line was gently provided by Dr. Fanelli Mirko,
University of Urbin, Italy.
Quantitative real time reverse transcription-PCR (qPCR)
Total RNA was extracted using TRIZOL reagent (Life
Technologies). Integrity and purity of RNAs were measured
by using Agilent 2100 Bioanalyzer (Agilent Technologies)
and reverse-transcribed by Quantitect Transcription kit
(Qiagen), according to the manufacturer’s instructions.
Oligos for qPCR were designed using the Primer express
program [14] with default parameters, with EEF1A1 and
TBP as references genes. qPCR reactions and calculations
were made as reported in [15, 16], mRNA from NHA cell
line was used as reference sample for cell line, while com-
mercially available RNAs (Agilent Technologies) from
brain of 4 healthy individuals were used in tissues gene
expression studies, respectively.
Mutational Analysis and copy number variation analysis
Genomic DNAs were extracted from fresh and frozen
peripheral blood leukocytes and from cell lines using an
automated DNA extractor (EZ1, Qiagen) and quantified
by Nanodrop (Thermo Scientific). Sequencing of TRIM8
coding region was performed in 70 patients. Primers
were designed using the Primer 3 Output program
(http://frodo.wi.mit.edu/primer3/) to amplify the 6 cod-
ing exons of TRIM8 (RefSeq NM_030912.2) gene includ-
ing the intronic flanking sequences. The amplified
products were subsequently purified and sequenced as
reported in [17]. All primers used in this study are avail-
able upon request. For TRIM8 gene copy number vari-
ation analysis, four normalization assays mapping to
HSA21 and four normalization DNAs were systematic-
ally included in each run as described [16]. Gene dosage
segments were classified as chromosomal “gain” or “loss”
if the absolute value of the predicted dosage was more
than 0.75 times the interquartile range of the difference
between observed and predicted values for each region.
Primer pairs were designed to amplify a fragment span-
ning the codon 132 that encodes for the catalytic domain
of IDH1. Sequence reactions were performed as reported
in [17].
miRNA expression analysis
A qPCR for miR-17 expression in glioma cell lines and tis-
sues was performed using TaqMan miRNA Reverse Tran-
scription kit according to the manufacturer’s instructions.
Reactions were set up in a 384-well plate using Taqman
Universal PCR Master Mix (Life Technology) and run in
an ABI Prism7900HT according to the manufacturer’s
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triplicate and the small nucleolar RNA U6 expression level
was used as an endogenous control. All qPCR reagents
were purchased from Life Technologies.
Dual-luciferase reporter assay and constructs
The entire genomic region of the miR-17-92 cluster
(1094 bp) was amplified by using gene-specific primers
and cloned into pcDNA3 expression vector (pcDNA3-
miR-17-92). The luciferase-UTR reporter plasmid was
constructed by introducing the TRIM8 3′-UTR into
pmiR-REPORT miRNA Expression Reporter Vector Sys-
tem (Life Technologies). The TRIM8 3′-UTR sequence
was amplified by PCR from HeLa cDNA. Mutagenesis
was used to delete miR-17 binding site using the Quick-
Change II kit (Stratagene). The pcDNA3-Flag-TRIM8-3′
UTR was generated by cloning the entire open reading
frame and 3′-UTR of TRIM8 amplified from HeLa cDNA
into pcDNA3-Flag vector. All constructs were verified by
sequencing. The reporter construct, pSV-Renilla (pRL-
SV40, Promega) and miR-17 mimic (or miR-17-5p hairpin
inhibitor or miR-20a mimic, Dharmacon) or pcDNA3-
miR-17-92 were transfected into H1299, HEK293 or
MCF-7 cells using Hyperfect Transfection Reagent (Qia-
gen) or Lipofectamine 2000 (Life Technologies). After
48 h, the cells were lysed in passive lysis buffer and
assayed for both firefly and renilla luciferase activity using
the Dual-GLO® Luciferase Assay System (Promega). Firefly
luciferase activity was normalized to Renilla luciferase
activity for each transfected well. Values are the mean ±
S.E.M. of three experimental replicates from two to four
independent transfections. Significance was determined by
a two-tailed unpaired t test for means.
MTT cell proliferation assay
Tumor cells were transfected with pcDNA3-myc-TRIM8
or empty vector using Lipofectamine LTX (Life Technolo-
gies) according to the manufacturer’s instructions and 24,
48 or 72 h after transfection MTT (3–2, 5-diphenyl tetra-
zolium bromide, Sigma) was added to each well of a
culture plate as described previously [7]. After incubation
at 37 °C for 4 h, the reaction was stopped by solubilization
with isopropanol. Absorbance at a wavelength of 570 nm
was measured. Each experiment was performed in
triplicate.
Clonogenic assay
Clonogenic assay was performed as previously described
[18]. In brief, 5 × 10e5 U87MG and three primary glio-
blastoma cells were transfected with 5 micrograms of
pcDNA3 vector coding for HA-TRIM8 or empty vector
by using Neon Transfection Device (Life Technologies).
48 h post electroporation, the cells were analyzed for
HA expression through immunofluorescence and platedin 96-well plates with a density of 0.8 cell/well. After
3 weeks, colonies defined as greater than 50 cells were
counted. Each set of experiments was performed in
triplicate.
TCGA mRNA, miRNA dataset and patients’ information
mRNA, miRNA expression data and clinical information
for the Glioblastoma Multiforme and Lower Grade Gli-
omas (LGG) datasets were downloaded from The Cancer
Genome Atlas (TCGA) data portal in January and June
2013 respectively (http://cancergenome.nih.gov/) [19]. We
analysed level 3 data for a total of 945 patients (567
glioblastoma and 378 LGG) with TRIM8 expression and
tumor grade information available. Data was quartile nor-
malized and log2 transformed. Among 378 patients with
LGG, 183 had WHO grade II, 195 had WHO grade III. To
perform overall survival (OS) and progression-free survival
(PFS) analyses, we selected 935 patients (564 glioblastoma
and 371 LGG) from the 945 patients, with both outcome
available information miRNA-based subtype classification.
Since grade II (n = 180, from the 935 patients) and
grade III (n = 191, from the 935 patients) gliomas differ
substantially in prognosis, survival analyses were per-
formed in each subgroup separately. To evaluate associ-
ation between TRIM8 CNV and tumor grade, a total of
526 patients (from the 945) with TRIM8 CNV informa-
tion available were selected (268 glioblastoma and 258
LGG). Clinical-pathological patients’ characteristics for
the TCGA GBM and LGG datasets are reported in
Additional file 2: Table S2.
Statistical methods
Continuous variables were reported as mean ± standard
deviation (SD) and as median along with IQR. Categor-
ical variables were reported as absolute and relative fre-
quencies. Normal distribution assumption was checked
by means of Q-Q plot, Shapiro-Wilks and Kolmogorov-
Smirnov tests.
Due to the deviation from normality distribution
assumption, all statistical analyses were performed using
the log-transformed expressions for TRIM8 in glioma
cell lines and tissues, whereas the square root transform-
ation was applied for miR-17-5p expression levels only.
Differences of TRIM8 in glioma tissues expression
between tumour grades (WHO grades II vs. III vs. IV)
were assessed using ANOVA model.
Histograms of TRIM8 copy numbers frequency distri-
butions were further represented with respect to tumor
grades. The linear trend of TRIM8 copy numbers across
tumor grades was tested using Mantel-Haenszel Chi-
Square. Boxplots of TRIM8 expression in tissue gliomas
with respect to each tumor grade and TRIM8 copy num-
ber available were also reported. Time-to-event analyses
were performed by univariable and multivariable Cox
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outcomes and the tertile values of TRIM8 expression
were used to categorize patients into lowest, medium
and highest expression groups. Risks were reported as
hazards ratios (HR) along with their 95 % confidence
interval (95 % CI). Multivariable Cox proportional haz-
ard models included the following covariates: TRIM8 ex-
pression (in tertiles), age, the presence of IDH1 mutation
and the presence of any treatment therapy (i.e. Chemo-
therapy, Radiotheraphy or both). Time to disease pro-
gression was defined as the time between diagnosis and
first evidence of disease progression, whereas time to
death was defined as the time between diagnosis and
death occurrence. Furthermore, Kaplan-Meier curves
were also reported along with p-value from log-rank test.
A p-value <0.05 was considered statistically significant.
All statistical analyses and graphs were performed by
using SAS Release 9.3 (SAS Institute, Cary, NC, USA)
and R (version 2.15.2, packages: gtools, car, survival)
software, respectively.
Results
TRIM8 is down regulated in higher-grade gliomas
TRIM8 RNA expression level was determined from 71
primary glioma cell lines: 8 (WHO grade I and II), 12 (III),
51 (IV) and 70 tumor tissues: 16 (WHO grade I and II),
10 (III), 44 (IV). TRIM8 relative expression ranged from
0.09 to 1.65 in glioma cell lines and 0.01-16.13 in tumor
tissues, respectively. We found a statistically significant
lower TRIM8 relative expression in grade IV, when com-
pared with grades II and III (p < 0.001) in both tumor tis-
sues and cell lines (Fig. 1a and b). In tumor tissue glioma,
median TRIM8 relative expressions were 0.49 in GBM
(IQR: 0.30-0.82), 0.81 in WHO grade III (IQR: 0.37-2.32)
and 2.61 in WHO grade I-II (IQR:1.52-6.14) glioma
(Fig. 1a). We next examined the transcriptional profile of
TRIM8 in an independent cohort, i.e. the TCGA cohort,
detecting a significant lower expression of TRIM8 in grade
III glioma (Median:0.65, IQR:0.32-1.23) as compared with
grade II glioma (Median: 1.05, IQR 0.63-1.79) (Fig. 1c).
GBM expression profile data were not analyzed and com-
pared as they were generated by a different platform com-
pared to LGG (https://tcga-data.nci.nih.gov/tcga/).
Low TRIM8 tissues expression level is associated with
unfavorable clinical outcome in WHO grade III gliomas
We evaluated the association between TRIM8 expression
and Overall Survival and Progression-free Survival in
180 grade II, 191 grade III and 564 grade IV gliomas of
TCGA cohort. Tertiles of TRIM8 expression were calcu-
lated within each tumor grade, separately.
In WHO grade III tumors, univariable Cox regression
analysis revealed a significant increase of mortality risk in
patients with the lowest TRIM8 expression levels (<0.45,first tertile) as compared to those with the highest levels
(>1.00, third tertile). Indeed, we estimated a HR of 0.09
(95 % CI: 0.04-0.22, p < 0.001) and 0.18 (95 % CI: 0.08-
0.36, p < 0.001) comparing the third and the second ter-
tiles with the first one, respectively. Such results were con-
firmed in the multivariable Cox regression analysis
comparing the third tertile to the first tertile (HR = 0.23,
95 % CI: 0.10-0.54, p = 0.001) (Fig. 1d). Moreover, univari-
able Cox analysis also evidenced a significant increase in
the risk of disease progression in patients with the lowest
TRIM8 expression levels with respect to those with the
highest level (third vs. first tertiles HR = 0.20, 95 % CI:
0.05-0.76, p = 0.018; second vs. first tertiles HR = 0.43;
95 % CI: 0.15-1.22, p = 0.114) (Fig. 1e). No significant dif-
ferences were found among tertiles group in multivariable
analysis, probably due to the low number of progression
events, with a consequent loss of statistical power. Overall
these data suggested that TRIM8 expression levels might
represent an independent predictor of survival in WHO
grade III gliomas. No statistically significant association
with OS and PFS were found in WHO grade II gliomas
and GBM.TRIM8 reduces cell proliferation in glioblastomas
To evaluate the effect of TRIM8 in glioma cell prolifera-
tion, we transfected U87MG glioma cells with a vector
expressing TRIM8 and measured cell viability by MTT
assay at 24, 48 and 72 h post transfection, respectively. Re-
sults showed that TRIM8 overexpression significantly re-
duced cell proliferation by about 25 % (Fig. 1f, p < 0.05,
Additional file 3: Figure S1A). We next analyzed the bio-
logical effect of TRIM8 expression by restoring expression
levels of TRIM8 in two representative GBM patients cell
lines. MTT assay confirmed that, in the presence of
TRIM8, the rate of cell proliferation is significantly re-
duced by about 30 % (Fig. 1g, p < 0.01).
We therefore investigated whether overexpression of
TRIM8 affects clonogenic potential of glioma cells as an in-
direct index of their tumorigenic potential. U87MG glioma
cells, transfected with expressing TRIM8 or control vector
(with transfection efficiency >80 %, measured by immuno-
fluorescence, data not shown), were plated at limiting dilu-
tion and the formation of large colonies (>50 cells) was
assessed after 3 weeks. The enforced expression of TRIM8
induced a significant reduction of clonogenic potential (p =
0.014) from the average number of 47.9 % colonies in
control-transfected cultures to 30.4 % in TRIM8 transfected
cells (Fig. 1h). Consistently these results were confirmed in
three primary glioblastoma cell lines (GBM3, GBM6, and
GBM19) with an average number of 55 %, 49.3 %, and
42.5 % colonies in control cultures, respectively, and 35.3 %.
39.3 %, and 28.9 %, respectively, in glioma TRIM8 express-
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Fig. 1 TRIM8 is downregulated in gliomas and affects cell proliferation. (a-c) Box-plots of TRIM8 tissues expression (a, c) and TRIM8 cells expression (b)
between tumor grades. qPCR was performed to measure the level of TRIM8 transcript in a total of 70 glioma tissues and cell lines (CSS) and 378 glioma
tissues specimens from TCGA LGG dataset. Kaplan-Meier curves for Overall Survival (d) and Progression-Free-Survival (e) according to TRIM8 tertiles of
expression levels in patients with tumor grade III (TCGA data). (f-g) The effect of TRIM8 expression on cell proliferation was assessed by MTT assay in
U87MG glioblastoma cell lines (f) and in patient glioma cell lines (g) transfected with pcDNA3 vector expressing TRIM8 or empty vector. The Y-axis
represents the absorbance value. (h-j) Effect of HA-TRIM8 expression and empty vector on in vitro clonogenic potential of U87MG cells (h) and three
patient glioblastoma cell lines, GBM3, GBM6, and GBM19 (j). Results are reported as mean percentage of clones from three independent experiments,
and error bars represent standard deviations. These experiments were repeated three independent times and similar results were obtained each time
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To investigate the mechanisms that may cause the
reduction of TRIM8 expression in glioma we sequenced
the coding and untranslated regions of TRIM8 in 70
patients detecting any likely pathogenic variant (data not
shown). Then we sought to determine TRIM8 copy
number by qPCR. TRIM8 copy number results were ob-
tained in 68 out of the70 patients from out cohort. We
detected a somatic heterozygous deletion encompassing
the full TRIM8 gene in 27 out of 68 (39.7 %) analyzed
glioma cells. We found a linear trend of TRIM8 copy
number across tumor grades (Fig. 2a, p = 0.025). Specif-
ically, a heterozygous deletion of TRIM8 was observed
in approximately 11.1 % of gliomas of WHO grades I
and II, 30.8 % of grade III, and 47.8 % of glioblastomas
(Fig. 2a).
To confirm this evidence, we used the available TRIM8
copy number information from the 526 of TCGA co-
hort, detecting a heterozygous deletion of TRIM8 gene
in 303 out of 526 (57.6 %) analyzed glioma tissues. Spe-
cifically, the loss of one copy of TRIM8 gene was ob-
served in approximately 9.9 % of gliomas of grade II,
32.8 % of grade III, and 91.8 % of glioblastomas (Fig. 2b,
p < 0.001). Loss of TRIM8 copy number was found sig-
nificantly associated to TRIM8 low expression level in
TCGA group (Fig. 2c-e).miR-17 regulates TRIM8 expression at the
post-transcriptional level
We screened the 3′UTR of TRIM8 by bioinformatic tools
to search for putative miRNAs binding sites. As a result,
we found that the 3′UTR of TRIM8 contains two putative
conserved miR-17 and miR-20a binding sites. To experi-
mentally in vitro test whether TRIM8 is directly targeted
by miR-17 and miR-20a, the 3′UTR of TRIM8 gene carry-
ing wild type and mutated miRNA seed was inserted into
a luciferase reporter vector and the entire genomic coding
region of the miR-17-92 cluster was cloned into pcDNA3
expression plasmid. We observed a luciferase reporter
activity reduced by 60 % in HEK293 cells co-transfected
with the 3′UTR TRIM8 and miR-17-92 expressing vectors
(p < 0.05, Fig. 3a).
Next, to test whether miR-17 or miR-20a directly target
the 3′UTR of TRIM8, HEK293 cells were co-transfectedwith 3′UTR TRIM8 reporter construct along with a syn-
thetic mimic of miR-17 or of miR-20a. As shown in Fig. 3b
the overexpression of miR-17 significantly reduced the
luciferase activity of the vector containing the 3′UTR of
TRIM8 when compared to the control (p = 0.005). Con-
sistently, deletion of the binding site abrogated this effect
(Fig. 3b). Collectively, these results indicated that the 3′
UTR of TRIM8 is targeted by miR-17.
Further we explored whether this regulation occurred
also for endogenous TRIM8. In keeping with our lucifer-
ase data, qPCR results showed a negative correlation
between miR-17 and TRIM8 expression levels in several
human cell lines including breast and glioma cells
(Fig. 3c). On the other hand, MCF-7 cells transfected
with miR-17 inhibitor had a slight increased expression
of TRIM8 mRNA when compared with miR control
inhibitor (Fig. 3d). Finally, we found a slight negative
correlation between TRIM8 and miR-17 expression in
glioma tissue in grade II (r = −0.172, p = 0.020) and
glioblastoma (r = −0.088, p = 0.038) patients from TCGA
cohort, supporting the assertion that miR-17 might con-
tribute to modulate TRIM8 expression in gliomas (data
not shown).
In order to assess whether miR-17 also regulates protein
level of TRIM8 in glioma cells, we co-transfected U87MG
cells with a pcDNA3-FLAG vector containing the ORF
and 3′UTR of TRIM8 (hereafter named TRIM8-3′UTR),
along with synthesized miR-17 or miR-17 inhibitor, re-
spectively. The level of TRIM8-tagged fusion protein was
reduced by miR-17 mimic and enhanced by miR-17 in-
hibitor (Fig. 3e). Overall these evidences demonstrate that
miR-17 regulates TRIM8 expression at both transcrip-
tional and post-transcriptional level by directly binding
the 3′UTR region of TRIM8.Discussion
Human gliomas are the most common and lethal neuro-
logical malignancies in adults. Our study is the first that
investigates the role of the E3 ubiquitin ligase TRIM8 in
glioma. We presented experimental evidences showing
that i) TRIM8 expression level is significantly decreased
in glioma and is inversely associated with glioma WHO
grades in both our own cases collection and in the inde-


























































Fig. 2 Loss of TRIM8 copy number in gliomas. a Frequency distribution of TRIM8 copy number, within each tumor grade, along with p-value from
Mantel-Haenszel Chi-Square test for linear trend. TRIM8 copy number in the gliomas was explored by using qPCR on DNA extracts from patient
glioma cell lines and peripheral blood. b Frequency distribution of TRIM8 CNV by tumor grade (TCGA data). c-e Boxplots of TRIM8 expression in tissue
gliomas by TRIM8 copy number for each tumor grade separately (TCGA data)
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death in WHO grade III tumours (TCGA dataset), and
iii) the overexpression of TRIM8 suppresses cell growth
and induces a significant reduction of clonogenic poten-
tial in both U87MG glioblasto ma and patient’s primary
glioma cell lines.
We investigated the molecular mechanism that can
explain the observed TRIM8 expression decrease. Our ex-
perimental data suggested that the inactivation of TRIM8in glioblastoma cells may occurs primarily through the
loss of gene copy number. Moreover we showed that
TRIM8 expression is regulated by miR-17 at transcrip-
tional and post-transcriptional level. Accumulating data
have indicated that the inhibition of miR-17 significantly
reduce cell viability and increases apoptotic activity in gli-
oma cell lines and the upregulation of this miRNA is asso-
ciated with advanced tumour progression and poor overall
survival of gliomas [20]. Our preliminary results suggest
Fig. 3 miR-17 regulates TRIM8 expression at the post-transcriptional level. a HEK293 cells were co-transfected with a reporter construct carrying
the 3′ UTR of TRIM8 and a pcDNA3-miR-17-92 or pcDNA3 empty vector. Luciferase activities were measured and normalized to the level of control
Renilla luciferase. b HEK293 cells were co-transfected with reporter constructs carrying the 3′UTR of TRIM8 or 3′ UTR of TRIM8 containing mutated
miR-17 complementary site and a synthetic mimic of miR-17, mimic of miR-20a, or miR-control (miR-CNT). c Detection of TRIM8 endogenous
expression by qPCR in MCF-7, HeLa, HEK293, and U87MG cell lines transfected with miR-17 mimic or miR-control. d TRIM8 endogenous expression
in MCF-7 cell lines transfected with miR-17 inhibitor or miR-control inhibitor. e Immunoblotting analysis by using indicated antibodies on whole
protein lysate from U87MG transfected with a construct carrying the ORF and 3′UTR of TRIM8 or the ORF and 3′ UTR of TRIM8 containing a
deletion of miR-17 complementary site and a miR-17 mimic, miR-17 inhibitor, or miR-control
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TRIM8 for glioma pathogenesis.
Our data corroborate mounting evidence showing a
downregulation of TRIM8 in different cancers and its role
in controlling cell growth. In fact, recent data showed that
TRIM8 low expression level correlates with nodal meta-
static progression in primary larynx squamous cell carcin-
oma and whose expression inhibits tumour cell colony
formation in vitro [8, 21]. Yet, we previously ascertained
that TRIM8 is an important component in controlling the
molecular switch that directs p53 toward transcriptional
activation of cell cycle arrest genes such as p21 and
GADD45 [7]. Finally, downregulation of TRIM8 was
shown to impair the p53-mediated cellular responses to
chemotherapeutic drugs in renal cell carcinoma [9].
In our study, the analysis of the TCGA datasets
evidenced a significant increase in the risk of death and
disease progression in WHO grade III tumours with thelowest TRIM8 expression levels compared to those with
the highest level. These results suggest that loss of
TRIM8 expression may be necessary for the transition
to a more aggressive phenotype typical of WHO grade
III gliomas as compared with WHO grade II tumours,
but it may have less effect on the clinical behaviour of
GBMs, suggesting a likely role of TRIM8 gene in glioma-
genesis and disease progression.
Many examples are showing that TRIM family members,
through their E3 ubiquitin ligases activity, are involved in
oncogenic processes such as cell proliferation and apop-
tosis [5, 22]. For instance, TRIM32 induces tumour necro-
sis factor (TNF)-mediated apoptosis through its direct
interaction and ubiquitylation of X-linked inhibitor of
apoptosis (XIAP) [23]. The E3 ubiquitin ligases activity of
TRIM13, TRIM19, TRIM24 and TRIM28 regulate the
stability or transcriptional activity of p53 that leads to the
control of apoptosis and DNA damage response [24].
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activation of nuclear and hormone receptors, play a key
role in the progression of leukaemia, as well as the devel-
opment of breast and prostate cancer [21]. Based on this
group of experimental data, we can hypothesize that de-
fects in TRIM8 E3 ligase activity in glioma cells might
promote carcinogenesis and cancerous growth by contrib-
uting to oncogenes stabilization and/or enhancing tumour
suppressors degradation.
Conclusions
Our data give preliminary evidences that TRIM8 may par-
ticipate in the carcinogenesis and progression of glioma
and that the transcriptional repression of TRIM8 might
have potential value for predicting poor prognosis in gli-
oma patients. Moreover, our preliminary results suggest
that TRIM8 and miR-17 may be part of a same circuit in-
volved in glioma pathogenesis, although further experi-
ments are needed to confirm the involvement of this
modulation in gliomagenesis.
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